BD Submits Pre-Market Approval Application to FDA
News Sep 07, 2016
Becton, Dickinson and Company (BD) announced that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the BD Onclarity™ HPV Assay, its human papillomavirus (HPV) test.
The BD Onclarity HPV Assay PMA is supported by data collected during a two-year, prospective, multi-center clinical trial with more than 33,000 women enrolled ― one of the largest clinical trials ever conducted by BD.
“The submission of BD’s HPV PMA application marks the completion of a significant undertaking,” said Doug White, vice president and general manager of Women’s Health & Molecular Diagnostics for BD. “Our goal is to provide clinical laboratories and clinicians with comprehensive cervical cancer screening solutions that include BD Onclarity HPV Assay, BD SurePath™ Pap Test and BD Totalys™ System processing automation.”
The submission seeks approval for use of the BD Onclarity HPV assay with BD SurePath specimens for detection of 14 high-risk HPV types to determine the need for referral to colposcopy for women 21 and older with abnormal (ASC-US) Pap test results and in women 30 years and older, the use of BD Onclarity together with cervical cytology to adjunctively screen for high-risk HPV and individually identify HPV genotypes 16, 18 and 45. BD is also seeking the use of the test as a first-line primary cervical cancer screening test for women 25 years and older.
BD intends to ultimately seek approval using HPV genotyping beyond 16, 18 and 45, in line with the genotyping capabilities of the assay’s design.
BD’s submission seeks approval to use the assay on the BD Viper™ LT System, which is a bench-top molecular platform currently FDA-cleared for chlamydia gonorrhea infection (CT/GC) testing. The BD Viper LT System automates sample processing, nucleic acid extraction, Real-Time Polymerase Chain Reaction (RT-PCR) amplification/detection and result reporting with minimal user intervention. The BD Viper LT System is part of the BD Totalys System, which automates cervical cancer screening including BD SurePath Pap Test slide preparation, imaging and slide review, combined with automated aliquot capabilities for ancillary testing.
Researchers have created a portable and fast-acting test that can distinguish Ebola infections from other fever-causing infectious diseases such as Lassa fever and malaria in around 30 minutes. Although further testing is required, this could be useful during febrile disease outbreaks.READ MORE